▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / IBO

IBO — IMPACT BIOMEDICAL INC.

—
NYSE · Health Care · Pharmaceuticals · CIK 1834105 ·
Last close
$0.45
Market Cap
$48.84M
52W High
$0.62
52W Low
$0.40
ADV30
30,186
Next earnings
—
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 3,000 2,000 -702,000 -699,000 16,745,000 10,000 2,733,000
Mar 2026 7,000 — -2,289,000 -2,287,000 17,086,000 20,000 2,375,000
Dec 2025 7,000 -415,000 -1,158,000 5,245,000 17,405,000 3,000 1,850,000
Sep 2025 18,000 17,000 -948,000 -1,470,000 18,208,000 12,000 27,061,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,672,000
Investing CF
$1,000
Financing CF
$373,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.43
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-51,794,000
Inventory
$63,000
Receivables
$199,000
ST Investments
—
EBIT TTM
$-14,934,000
Pretax Income TTM
$-15,456,000
Interest Exp TTM
$522,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$35,000
EBITDA
$-3,952,000
Free Cash Flow
$1,016,875
Enterprise Value
$52,079,016
Total Cash
$10,000
Total Debt
$0
Shares Out
107,821,231
Trailing EPS
$0.88
Book Value
$0.10
ROE
23.5%
ROA
-17.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 32,000 -4,270,000 -11,838,000 17,405,000 1,850,000 — -1,890,000
Dec 2024 0 -3,397,000 -24,708,000 20,290,000 13,053,000 — -2,854,000
Dec 2023 0 -4,028,000 -4,336,000 44,633,000 16,371,000 — -2,851,000
Dec 2022 50,000 -3,404,000 -7,051,000 46,497,000 13,828,000 — -2,242,000
Dec 2021 — — — — — — —

Peers — same industry

TickerNameMarket CapLastDaily %
NSRX Nasus Pharma Ltd $47.66M $4.07 —
HYPD HYPERION DEFI, INC. $50.66M $3.26 —
VICP Vicapsys Life Sciences, Inc. $46.94M $1.45 —
MCRB Seres Therapeutics, Inc. $46.81M $4.66 —
BHST BIOHARVEST SCIENCES INC. $46.47M $2.05 —

News headlines (Yahoo Finance, 1h cache)

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
2026-04-03 17:52 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →